Therapy of mRCC beyond mTOR-inhibition in clinical practice: Results of a retrospective analysis

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 5, 2014, Pages 823-827

  Maute, Luise ^a   Grünwald, Viktor ^b   Weikert, Steffen ^c   Kube, Ulrich ^d   Gauler, Thomas ^e   Kahl, Christoph ^f   Burkholder, Iris ^g   Bergmann, Lothar ^a  

^a GOETHE UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Practice for Urology   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^g Saarland University of Applied Sciences   (Germany)

Author keywords

Everolimus; mTOR; Renal cancer; Sequential treatment

Indexed keywords

DOVITINIB; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84901605959     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1610-x     Document Type: Article

References (26)

1. Bergmann L, Goebell PJ, Kube U et al (2013) Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study. Onkologie 36(3):95-100
2. Bergmann L, Beck J, Bothe K et al (2014) Treatment algorithm for metastatic renal cell carcinoma. Recommendations based on evidence and clinical practice. Oncol Res Treat (in press)
3. Bergmann L, Luise Maute L, Guschmann L (2014b) Drug profile of temsirolimus for advanced renal cell carcinoma. Expert Rev Anti-cancer Ther 14(1):9-21
4. Beuvink I, Boulay A, Fumagalli S et al (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120(6):747-759 (Pubitemid 40568794)
5. Bukowski RM (2012) Temsirolimus: a safety and efficacy review. Expert Opin Drug Saf 11(5):861-879
6. Cho I, Chung J (2012) Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol 53:217-228
7. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr (1999) Rising incidence of renal cell cancer in the United States. JAMA 281(17):1628-1631 (Pubitemid 29211773)
8. Del Bufalo D, Ciuffreda L, Trisciuoglio D et al (2006) Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66(11):5549-5554 (Pubitemid 43927103)
9. Dutcher JP, de Souza P, McDermott D et al (2009) Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26(2):202-209
10. Escudier B, Albiges L, Sonpavde G (2013) Optimal management of metastatic renal cell carcinoma: current status. Drugs 73(5):427-438
11. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5(8):671-688 (Pubitemid 44151605)
12. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674
13. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98(18):1331-1334 (Pubitemid 44530728)
14. Hutson TE, Escudier B, Esteban E et al (2013) Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol [Epub ahead of print]
15. Janzen NK, Kim HL, Figlin RA, Belldegrun AS (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30(4):843-852 (Pubitemid 37485197)
16. Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132(1):27-42
17. Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH (2002) Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 11(2):171-178 (Pubitemid 34478435)
18. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449-456
19. Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 116(18):4256-4265
20. Motzer RJ, Barrios CH, Kim TM et al (2013) Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31(Suppl; abstr 4504)
21. Pantuck AJ, Seligson DB, Klatte T et al (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109(11):2257-2267 (Pubitemid 46801555)
22. Populo H, Lopes JM, Soares P (2012) The mTOR signalling pathway in human cancer. Int J Mol Sci 13(2):1886-1918
23. Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931-1939
24. Shinohara ET, Cao C, Niermann K et al (2005) Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24(35):5414-5422 (Pubitemid 43080085)
25. Wu C, Wangpaichitr M, Feun L et al (2005) Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 4(1):25
26. Yuan R, Kay A, Berg WJ, Lebwohl D (2009) Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2:45